NASDAQ:WINT Windtree Therapeutics Q2 2024 Earnings Report $0.02 +0.00 (+20.00%) As of 10:01 AM Eastern ProfileEarnings History Windtree Therapeutics EPS ResultsActual EPS-$1,045.50Consensus EPS -$405.50Beat/MissMissed by -$640.00One Year Ago EPSN/AWindtree Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AWindtree Therapeutics Announcement DetailsQuarterQ2 2024Date8/19/2024TimeAfter Market ClosesConference Call DateTuesday, August 20, 2024Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Windtree Therapeutics Earnings HeadlinesWindtree Therapeutics Delays Filing of Annual ReportApril 1, 2026 | tipranks.comCommLoan Achieves Nationwide Regulatory Approval Across All 50 StatesMarch 17, 2026 | prnewswire.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.June 1 at 1:00 AM | Weiss Ratings (Ad)Windtree Therapeutics Announces Sudden Departure of President and COOJanuary 17, 2026 | theglobeandmail.comWindtree sells heart drug assets, keeps a cut of any future breakthroughDecember 30, 2025 | msn.comWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesDecember 23, 2025 | finance.yahoo.comSee More Windtree Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Windtree Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Windtree Therapeutics and other key companies, straight to your email. Email Address About Windtree TherapeuticsWindtree Therapeutics (NASDAQ:WINT) is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants. The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli. Windtree’s pipeline includes aerosolized and intratracheal formulations intended for rapid distribution in the lung, including programs that have advanced through preclinical studies and early-stage clinical trials. These programs aim to offer an alternative to animal-derived surfactants and to target patient populations with significant unmet medical needs. Headquartered in Warrington, Pennsylvania, Windtree collaborates with academic research centers and clinical investigators across the United States and Europe to conduct its development programs. The company’s activities encompass formulation optimization, toxicology testing, and multi-site clinical evaluations, supported by partnerships that extend its reach into critical care and neonatal intensive care settings. Under the leadership of President and CEO Michael Ott, Windtree maintains a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The organization is committed to advancing its pipeline through regulatory interactions and clinical milestones in pursuit of therapies that can improve outcomes for patients with serious cardiopulmonary disorders.View Windtree Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysBest Buy’s AI Laptop Boost Sparks Hope for a BBY TurnaroundDollar Tree Keeps Winning After Family Dollar Divorce Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
